S. Reske

发表

Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

H. Schirrmeister, G. Glatting, J. Hetzel, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures

H. Schirrmeister, G. Glatting, K. Nuessle, 2001, European Journal of Nuclear Medicine.

Improved non-invasive T-Staging in non-small cell lung cancer by integrated18F-FDG PET/CT

F. Mottaghy, G. Glatting, A. Buck, 2007, Nuklearmedizin.

Delusional infestation: Neural correlates and antipsychotic therapy investigated by multimodal neuroimaging

C. Schönfeldt-Lecuona, R. C. Wolf, S. Reske, 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Klemens Scheidhauer, Ali Guermazi, Felix M Mottaghy, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dissociating a Common Working Memory Network from Different Neural Substrates of Phonological and Spatial Stimulus Processing

Henrik Walter, Sven N. Reske, Bartosz Zurowski, 2002, NeuroImage.

FDG-PET for clinical use

S. Reske, J. Kotzerke, 2001, European Journal of Nuclear Medicine.

FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.

S. Reske, J. Kotzerke, 2001, European journal of nuclear medicine.

Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma

S. Reske, A. Guhlmann, J. Kotzerke, 1999, European Journal of Nuclear Medicine.

Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test.

G. Glatting, S. Reske, K. Hohl, 2007, Medical physics.

Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines

G. Glatting, S. Reske, R. Schmid, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Cranial Neuronavigation with Direct Integration of 11C Methionine Positron Emission Tomography (PET) Data – Results of a Pilot Study in 32 Surgical Cases

H. P. Richter, S. Reske, V. Braun, 2002, Acta Neurochirurgica.

First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine

Thomas Kull, Felix M Mottaghy, Gerhard Glatting, 2008, Journal of Nuclear Medicine.

Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases.

G. Glatting, S. Reske, A. Schulz, 2011, Blood.

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

Markus Luster, Thomas Kull, Gerhard Glatting, 2010, Journal of Nuclear Medicine.

Intensification of the Conditioning Regimen for Patients with high-risk AML and MDS: 3 year Experience of using an188 Re — Labelled anti — CD 66 Monoclonal Antibody

R. Schlenk, H. Döhner, G. Glatting, 2003 .

A comparison of the biodistribution and biokinetics of 99mTc-anti-CD66 mAb BW 250/183 and 99mTc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy

G. Glatting, S. Reske, G. Hale, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.

H. Döhner, G. Glatting, A. Buck, 2001, Blood.

Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2

H. Walter, F. Mottaghy, S. Reske, 2010, Neurology.

Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD

S. Reske, B. Krause, A. Ludolph, 2005, Annals of neurology.

TABLE 1 Number of Patients with FDG PET and Bone Scintigraphy in 56

S. Reske, J. Kotzerke, F. Moog, 2006 .

18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

S. Reske, A. Guhlmann, M. Bangerter, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study.

S. Reske, M. Schreckenberger, B. Neumaier, 2004, Cancer biotherapy & radiopharmaceuticals.

Quantification of 18F-FDG uptake in non-small cell lung cancer: a feasible prognostic marker?

G. Glatting, A. Buck, S. Reske, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.

G. Glatting, S. Reske, P. Möller, 2003, Cancer biotherapy & radiopharmaceuticals.

Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment

H. Heimpel, S. Reske, M. Bangerter, 1999 .

Comparing time activity curves using the Akaike information criterion

Thomas Kull, Sven N. Reske, Gerhard Glatting, 2009, Physics in medicine and biology.

Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings.

K. Nuessle, S. Reske, A. Rieber, 2001, AJR. American journal of roentgenology.

1011-116 Myocardial Rb Extraction Fraction: Determination in Humans

G. Glatting, S. Reske, V. Hombach, 1995 .

Structured treatment interruption in patients with alveolar echinococcosis

A. Buck, S. Reske, W. Kratzer, 2004, Hepatology.

Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography.

H. Schirrmeister, S. Reske, W. Kratzer, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Analysing saturable antibody binding based on serum data and pharmacokinetic modelling

G. Glatting, S. Reske, P. Kletting, 2011, Physics in medicine and biology.

Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.

K. Schwarz, G. Glatting, S. Reske, 2007, Cancer research.

Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography.

H. Schirrmeister, S. Reske, A. Guhlmann, 2001, Thyroid : official journal of the American Thyroid Association.

Is a preoperative multidiagnostic approach to predict surgical resectability of periampullary tumors still effective?

S. Reske, H. Brambs, S. Pauls, 2001, American journal of surgery.

Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia

G. Glatting, S. Reske, B. Neumaier, 1999, European Journal of Nuclear Medicine.

Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT

T. Mattfeldt, G. Glatting, A. Buck, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Recent advances in bone marrow scanning

S. Reske, 2005, European Journal of Nuclear Medicine.

New diagnostic imaging procedures in Hodgkin's disease.

H. Heimpel, S. Reske, M. Bangerter, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Bone marrow immunoscintigraphy compared with conventional bone scintigraphy for the detection of bone metastases.

S. Reske, U. Buell, M. Sohn, 1993, Acta oncologica.

Synthesis and biodistribution of 3'-fluoro-5-[(131)I]iodo-2'-deoxyuridine: a comparative study of [(131)I]FLIdU and [(18)F]FLT.

A. Buck, S. Reske, B. Neumaier, 2007, Nuclear medicine and biology.

Fluoro-3-Deoxythymidine ( [ 18 F ]-FLT ) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease

A. Buck, S. Reske, M. Bangerter, 2003 .

Initial results in the assessment of multiple myeloma using 18F-FDG PET

H. Döhner, H. Schirrmeister, S. Reske, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Iterative reconstruction for attenuation correction in positron emission tomography: maximum likelihood for transmission and blank scan.

G. Glatting, S. Reske, M. Wuchenauer, 1999, Medical physics.

131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging

L. Mortelmans, S. Reske, R. Moncayo, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings.

S. Reske, A. Rieber, R. Kreienberg, 2002, Radiology.

Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography.

K. Nuessle, S. Reske, A. Rieber, 2000, Gynecologic oncology.

Radiofluorination of PSMA-HBED via Al18F2+ Chelation and Biological Evaluations In Vitro

S. Reske, C. Solbach, A. Beer, 2015, Molecular Imaging and Biology.

Radiosynthesis of [18F]FEt-Tyr-urea-Glu ([18F]FEtTUG) as a new PSMA ligand

S. Reske, C. Solbach, H. Machulla, 2013, Journal of Radioanalytical and Nuclear Chemistry.

One pot radiofluorination of a new potential PSMA ligand [Al18F]NOTA‐DUPA‐Pep

S. Reske, C. Solbach, H. Machulla, 2012 .

Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep).

S. Reske, C. Solbach, H. Machulla, 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Brain metastasis in lung cancer

T. Wibmer, F. Mottaghy, A. Buck, 2010, Nuklearmedizin.

Use of integrated FDG-PET/CT in sarcoidosis.

F. Mottaghy, A. Buck, S. Reske, 2008, Clinical imaging.

Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours

F. Mottaghy, A. Buck, S. Reske, 2006, Journal of internal medicine.

Therapy for Patients with Rectal Carcinoma

R. Dummer, S. Reske, W. Scheithauer, 1999, Oncology Research and Treatment.

Intracoronary β-Irradiation With a Liquid 188Re-Filled Balloon Six-Month Results From a Clinical Safety and Feasibility Study

S. Reske, V. Hombach, J. Wöhrle, 2000 .

Bone scintigraphy: procedure guidelines for tumour imaging

L. Mortelmans, S. Reske, R. Moncayo, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.

S. Reske, J. Kotzerke, F. Moog, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

F-18 Fluorodeoxyglucose (FDG) and C-Reactive Protein (CRP).

G. Glatting, S. Reske, A. Guhlmann, 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?

S. Reske, A. Guhlmann, M. Sarkar, 1999, European Journal of Nuclear Medicine.

Diagnosis ofpancreatic cancer by 2(18F) -fluoro-2-deoxy- D-glucose emission tomography

H. Friess, S. Reske, M. Ebert, 1995 .

Cellular origin and molecular mechanisms of 18F-FDG uptake: is there a contribution of the endothelium?

A. Buck, S. Reske, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.

G. Glatting, S. Reske, F. Gansauge, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy

S. Reske, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?

H. Schirrmeister, S. Reske, H. Beger, 2000, American journal of surgery.

[Positron-emission tomography in the diagnosis of abdominal tumors].

H. Schirrmeister, S. Reske, A. Guhlmann, 1998, Schweizerische medizinische Wochenschrift.

2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.

H. Friess, G. Glatting, S. Reske, 1995, Radiology.

[Positron emission tomography in diagnosis of renal cell carcinoma].

S. Reske, R. Hautmann, J. Kotzerke, 1996, Der Urologe. Ausg. A.

Cost-Effectiveness of Hybrid PET/CT for Staging of Non–Small Cell Lung Cancer

F. Mottaghy, G. Glatting, A. Buck, 2010, The Journal of Nuclear Medicine.

Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.

S. Reske, S. Feuerlein, O. Klass, 2012, European journal of radiology.

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging

L. Mortelmans, S. Reske, R. Moncayo, 2003, European journal of nuclear medicine and molecular imaging.

Auger electron emitter against multiple myeloma--targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine.

F. Mottaghy, G. Glatting, S. Reske, 2011, Nuclear medicine and biology.

Preferential Tumor Targeting and Selective Tumor Cell Cytotoxicity of 5-[131/125I]Iodo-4′-Thio-2′-Deoxyuridine

G. Glatting, S. Reske, A. Morgenroth, 2008, Clinical Cancer Research.

In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model.

G. Glatting, S. Reske, R. Schmid, 2001, Cancer research.

Cancer Model for Positron Emission Tomography in a Murine Pancreatic-deoxyuridine as Tracer ′ F ] Fluoro-218 Evaluation of 5-[ In Vivo

G. Glatting, S. Reske, F. Greten, 2001 .

PET and restaging of malignant lymphoma including residual masses and relapse

S. Reske, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.

H. Schirrmeister, G. Glatting, K. Nuessle, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RADIOIMMUNOIMAGING FOR DIAGNOSIS OF BONE MARROW INVOLVEMENT IN BREAST CANCER AND MALIGNANT LYMPHOMA

S. Reske, J. Karstens, U. Buell, 1989, The Lancet.

[Imaging of the normal skeletal system with 18F Na-PET compared with conventional skeletal scintigraphy using Tc99m-MDP].

H. Schirrmeister, S. Reske, M. Rentschler, 1998, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Elevated FDG uptake in the lactating human breast.

H. Schirrmeister, S. Reske, A. Buck, 2001, Clinical nuclear medicine.

Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.

J Kotzerke, G Glatting, H. Schirrmeister, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of β-amyloid plaques

F. Mottaghy, G. Glatting, A. Buck, 2007, Nuklearmedizin.

Viability as seen with radiolabelled fatty acids — a new approach to a challenqinq problem

S. Reske, 2004, European Journal of Nuclear Medicine.

Viability as seen with radiolabelled fatty acids — a new approach to a challenqinq problem

S. Reske, 1994, European Journal of Nuclear Medicine.

Lymph node staging in lung cancer using [18F]FDG-PET.

H. Schirrmeister, G. Glatting, A. Buck, 2004, The Thoracic and cardiovascular surgeon.

Treatment of radioactive decay in pharmacokinetic modeling: influence on parameter estimation in cardiac 13N-PET.

G. Glatting, S. Reske, 1999, Medical physics.

67Ga scintigraphy: procedure guidelines for tumour imaging

L. Mortelmans, S. Reske, R. Moncayo, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

123I-ITdU–Mediated Nanoirradiation of DNA Efficiently Induces Cell Kill in HL60 Leukemia Cells and in Doxorubicin-, β-, or γ-Radiation–Resistant Cell Lines

G. Glatting, A. Buck, S. Reske, 2007, Journal of Nuclear Medicine.

FTDP‐17: An early‐onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation

S. Reske, P. Heutink, A. Ludolph, 1999, Annals of neurology.

Both total chain length and position of dimethyl-branching effect the myocardial uptake and retention of radioiodinated analogues of 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP)

S. Reske, M. Goodman, G. Kirsch, 1996, Annals of nuclear medicine.

Possible site of the in vivo disposition of sodium nitroprusside in the rat

S. Reske, V. Kreye, 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.

G. Glatting, S. Reske, K. Hohl, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Captopril mediated decrease of aortic regurgitation.

S. Reske, H. Mattern, J. Kropp, 1985, British heart journal.

Synthesis of 15-(4-[131I]iodophenyl)pentadecanoic acid (p-IPPA) via tin-precursor using Chloramine-T as an oxidant

S. Reske, C. Solbach, H. Machulla, 2010 .

Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration

G. Glatting, S. Reske, I. Mader, 2004, Movement disorders : official journal of the Movement Disorder Society.

Labelling of a monoclonal antibody with 68Ga using three DTPA-based bifunctional ligands and their in vitro evaluation for application in radioimmunotherapy

S. Reske, B. Neumaier, B. Koop, 2007 .

99Tcm-methoxy-isobutyl-isonitrile SPECT to evaluate a perfusion index from regional myocardial uptake after exercise and at rest. Results of a four hour protocol in patients with coronary heart disease and in controls.

S. Reske, H. Kaiser, U. Buell, 1990, Nuclear medicine communications.

[Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].

S. Reske, R. Hautmann, R. Bachor, 1995, Der Urologe. Ausg. A.

Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?

T. Mattfeldt, H. Schirrmeister, S. Reske, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?

H. Schirrmeister, S. Reske, H. Beger, 2000, American journal of surgery.

Synthesis and labelling of Df-DUPA-Pep with gallium-68 and zirconium-89 as new PSMA ligands

S. Reske, C. Solbach, H. Machulla, 2014, Journal of Radioanalytical and Nuclear Chemistry.

Intracoronary b -Irradiation With a Liquid 188 Re-Filled Balloon Six-Month Results From a Clinical Safety and Feasibility Study

S. Reske, V. Hombach, J. Wöhrle, 2000 .

Cardiac metabolism of I-123 phenyl-pentadecanoic acid

S. Reske, 1987 .

The Metabolism of Radioiodinated Free Fatty Acids in the Heart. Physiological Basis and Cardiac Biokinetics

S. Reske, 1985 .

Optimal preloading in radioimmunotherapy with anti-cD45 antibody.

G. Glatting, S. Reske, M. Luster, 2011, Medical physics.

Determination of the Myocardial Rubidium Extraction Fraction: Theoretical Investigation

G. Glatting, S. Reske, R. Weller, 1997 .

Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.

H. Schirrmeister, S. Reske, A. Guhlmann, 2002, Cancer biotherapy & radiopharmaceuticals.

15(p-['231]Iodophenyl)Penadecanoic Acid as Tracer of Lipid Metabolism: Comparisonwith [1-'4C]PalmiticAcid in MurineTissues

S. Reske, H. Machulla, C. Winkler, 2006 .

Experimental and clinical experience with iodine 123-labeled iodophenylpentadecanoic acid in cardiology

S. Reske, 1994, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

15(p-[123I]Iodophenyl)pentadecanoic acid as tracer of lipid metabolism: comparison with [1-14C]palmitic acid in murine tissues.

S. Reske, H. Machulla, C. Winkler, 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparative evaluation of labelling patterns and turnover of lipids, tagged by 15 /p-123I-phenyl-/ pentadecanoic and 1-14C-palmitic acid

S. Reske, H. Machulla, K. Reichmann, 1984 .

Synthesis of no-carrier-added 6-[11C]methyl-l-DOPA

S. Reske, C. Solbach, H. Machulla, 2012, Journal of Radioanalytical and Nuclear Chemistry.

Single photon emission tomography imaging of myocardial oxidative metabolism with 15-(p-[123I]iodophenyl) pentadecanoic acid in patients with coronary artery disease and aorto-coronary bypass graft surgery

S. Reske, F. Knapp, H. Biersack, 2004, European Journal of Nuclear Medicine.

Cardiac metabolism of omega-(p-iodo-phenyl)-pentadecanoic acid: a gas-liquid chromatographic-mass spectrometric analysis.

S. Reske, H. Machulla, H. Egge, 1984, Journal of lipid research.

Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues.

G. Glatting, S. Reske, A. Morgenroth, 2009, Bioorganic & medicinal chemistry letters.

Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer.

S. Reske, V. Drendel, C. Jilg, 2012, The Journal of urology.

Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode.

G. Glatting, S. Reske, R. Weller, 2004, Cancer biotherapy & radiopharmaceuticals.

Radiation dosimetry and biodistribution of the beta-amyloid plaque imaging tracer 11C-BTA-1 in humans

F. Mottaghy, G. Glatting, S. Reske, 2007, Nuklearmedizin.

Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy

G. Glatting, S. Reske, A. Beer, 2015, PloS one.

Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: a simulation study.

G. Glatting, S. Reske, P. Kletting, 2011, Zeitschrift fur medizinische Physik.

Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.

G. Glatting, S. Reske, P. Kletting, 2010, Cancer biotherapy & radiopharmaceuticals.

Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia.

F. Mottaghy, G. Glatting, A. Buck, 2008, Cancer biotherapy & radiopharmaceuticals.

Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings.

G. Glatting, S. Reske, A. Guhlmann, 1998, Radiology.

Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy.

F. Mottaghy, G. Glatting, S. Reske, 2012, Medical physics.

Determination of individual organ masses for (90)Y-anti-CD66 radioimmunotherapy: influence on therapy planning.

G. Glatting, S. Reske, P. Kletting, 2011, Zeitschrift fur medizinische Physik.

Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy.

H. Schirrmeister, A. Buck, S. Reske, 2003, Cancer biotherapy & radiopharmaceuticals.

Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.

R. Schlenk, H. Döhner, G. Glatting, 2006, Haematologica.

[PET and PET/CT in relapsing prostate carcinoma].

G. Glatting, S. Reske, N. Blumstein, 2006, Der Urologe. Ausg. A.

Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog.

F. Mottaghy, A. Buck, S. Reske, 2006, Nuclear medicine and biology.

Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography.

W. Vach, S. Reske, V. Drendel, 2014, The Journal of urology.

Assessment and Quantification of Regional Arterial Perfusion Reserve in Patients with Peripheral Occlusive and Small-Vessel Disease by Rubidium 82-Positron Emission Tomography

S. Reske, V. Hombach, G. Wierse, 1996 .

PET Assessment of Lymphoma: Beyond (18)F-Fluorodeoxyglucose.

S. Reske, 2006, PET clinics.

Accurate Preoperative Localization of Parathyroid Adenomas With C-11 Methionine PET/CT

S. Reske, B. Boehm, M. Luster, 2013, Annals of surgery.

Positron emission tomography (PET) for staging of solitary plasmacytoma.

H. Schirrmeister, A. Buck, S. Reske, 2003, Cancer biotherapy & radiopharmaceuticals.

Modeling Radioimmunotherapy with Anti-CD20 Antibody – Optimal Preload Depending on Lymphoma Transcapillary Solute Exchange

G. Glatting, S. Reske, P. Kletting, 2009 .

Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.

G. Glatting, S. Reske, M. Rentschler, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Hyperthermia: Different Methods, Different Aims, and Different Problems

R. Dummer, S. Reske, W. Scheithauer, 1999, Oncology Research and Treatment.

[F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes].

H. Schirrmeister, A. Buck, S. Reske, 1999, NuclearMedicine.

Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and 11C-methionine positron emission tomography in resection of glioblastoma: a prospective study

Sven N Reske, Ambros J Beer, Ralph König, 2018, Neurosurgical Review.

123I-phenylpentadecanoic acid as a tracer of cardiac free fatty acid metabolism. Experimental and clinical results.

S. Reske, 1985, European heart journal.

Cardiac metabolism of 15 (p-I-123 phenyl-) pentadecanoic acid after intracoronary tracer application.

S. Reske, H. Machulla, K. Reichmann, 1984, European journal of radiology.

Relation of Myocardial Blood Flow and Initial Cardiac Uptake of 15-(p-123I-Phenyl)-Pentadecanoic Acid in the Canine Heart

S. Reske, H. Machulla, W. Eichelkraut, 1984, Nuklearmedizin.

Synthesis of 15-(4-[11C]methylphenyl)pentadecanoic acid (MePPA) via Stille cross-coupling reaction

S. Reske, C. Solbach, H. Machulla, 2011 .

Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer

H. Döhner, S. Reske, R. Küfer, 2010, Case reports in medicine.

[Lymph node staging of bladder neck carcinoma with positron emission tomography].

S. Reske, R. Hautmann, J. Kotzerke, 1999, Der Urologe. Ausg. A.

Intracoronary &bgr;‐Irradiation With a Rhenium‐188‐Filled Balloon Catheter: A Randomized Trial in Patients With De Novo and Restenotic Lesions

S. Reske, V. Hombach, J. Wöhrle, 2003, Circulation.

Radiolabeled DNase, a potential indicator for noninvasive detection of tissue damage

S. Reske, K. Reske, C. Winkler, 2004, European Journal of Nuclear Medicine.

Adenovirus-delivered siRNA.

S. Reske, Changxian Shen, 2004, Methods in molecular biology.

Effect of myocardial perfusion and metabolic interventions on cardiac kinetics of phenylpentadecanoic acid (IPPA) I 123

S. Reske, H. Machulla, S. Schön, 2004, European Journal of Nuclear Medicine.

131I/123I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging

L. Mortelmans, S. Reske, R. Moncayo, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Radiosynthesis of carbon-11 labeled 6-methyldopamine ([¹¹C]MeDA).

S. Reske, C. Solbach, H. Machulla, 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Improved Synthesis and in Vitro Stability Test of Rhenium-188 Labeled Radiopharmaceuticals for Potential Use in Radiation Synovectomy

S. Reske, K. Grillenberger, 1997 .

Mono- and dimethylbenzyls as new protecting groups for no-carrier-added nucleophilic aromatic radiofluorination

S. Reske, C. Solbach, H. Machulla, 2011 .

Rhenium-188 labeled hydroxyapatite and rhenium-188 sulfur colloid. In vitro comparison of two agents for radiation synovectomy.

S. Reske, S. Glatz, K. Grillenberger, 1997, Nuklearmedizin. Nuclear medicine.

Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis.

G. Glatting, S. Reske, A. Guhlmann, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

In vivo assessment of phagocytic properties of Kupffer cells.

L. Feinendegen, S. Reske, K. Vyska, 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors.

F. Mottaghy, G. Glatting, S. Reske, 2011, Chemistry.

Pharmacokinetics of 99Tcm-pertechnetate and 188Re-perrhenate after oral administration of perchlorate: option for subsequent care after the use of liquid 188Re in a balloon catheter.

S. Reske, A. Guhlmann, M. Rentschler, 1998, Nuclear medicine communications.

[Dosimetry fundamentals of endovascular therapy using Re-188 for the prevention of restenosis after angioplasty].

G. Glatting, S. Reske, M. Rentschler, 1998, Nuklearmedizin. Nuclear medicine.

S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells

A. Buck, S. Reske, Changxian Shen, 2003, Cancer Gene Therapy.

Synthesis and Biologic Study of IV-14, a New Ribonucleoside Radiotracer for Tumor Visualization

S. Reske, A. Morgenroth, T. Kull, 2009, Journal of Nuclear Medicine.

Triplex forming oligonucleotide targeted to 3'UTR downregulates the expression of the bcl-2 proto-oncogene in HeLa cells.

S. Reske, A. Buck, M. Bachem, 2001, Nucleic acids research.

Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose?

S. Reske, S. Deisenhofer, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.

Sven N Reske, Bernd Neumaier, Andreas Buck, 2003, Cancer research.

Gene silencing by adenovirus‐delivered siRNA

S. Reske, Changxian Shen, M. Winkler, 2003, FEBS letters.

Pro-apoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells.

A. Buck, S. Reske, Changxian Shen, 2009, Anticancer research.

Chromosome instability and tumor lethality suppression in carcinogenesis

A. Buck, S. Reske, Changxian Shen, 2008, Journal of cellular biochemistry.

Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer

J Kotzerke, J van den Hoff, G Glatting, 2003, Nuklearmedizin.

New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

M. Picchio, S. Reske, C. Stief, 2016, European urology.

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

G. Glatting, S. Reske, N. Blumstein, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Production of Zr-89 on a PETtrace cyclotron

S. Reske, C. Solbach, H. Machulla, 2013 .

[11C]Choline PET/CT for Targeted Salvage Lymph Node Dissection in Patients with Biochemical Recurrence after Primary Curative Therapy for Prostate Cancer

Richard E. Hautmann, Felix M. Mottaghy, F. Mottaghy, 2008, Urologia Internationalis.

Experimental basis of metabolic imaging of the myocardium with radioiodinated aromatic free fatty acids.

S. Reske, F. Knapp, C. Winkler, 1986, American journal of physiologic imaging.

Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET

A. Buck, S. Reske, N. Blumstein, 2008, Nuklearmedizin.

Breast scintigraphy: procedure guidelines for tumour imaging

Sven N. Reske, Richard P. Baum, Lorenzo Maffioli, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.

Torsten Mattfeldt, Gerhard Glatting, Sven N Reske, 2002, Cancer research.

Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.

H. Friess, M. Büchler, S. Reske, 1995, Gut.

Assessment of Regional Myocardial Uptake and Metabolism of ω-(p-123I-Phenyl) Pentadecanoic Acid with Serial Single-Photon Emission Tomography

S. Reske, H. Biersack, K. Lackner, 1982, Nuklearmedizin.

Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells

S. Reske, C. Friesen, K. Debatin, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Brief S2k guidelines – Merkel cell carcinoma

S. Reske, D. Vordermark, C. Assaf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells

Sven N. Reske, Jörg Kotzerke, S. Reske, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation

S. Reske, G. Steinbach, D. Bunjes, 2009, Nuklearmedizin.

Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i.

G. Glatting, A. Buck, S. Reske, 2006, Nuklearmedizin. Nuclear medicine.

Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.

H. Döhner, G. Glatting, A. Buck, 2002, Cancer biotherapy & radiopharmaceuticals.

Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation

H. Döhner, G. Glatting, A. Buck, 2001, European Journal of Nuclear Medicine.

Modelling radioimmunotherapy with anti-CD45 antibody to obtain a more favourable biodistribution

F. Király, G. Glatting, S. Reske, 2009, Nuklearmedizin.

Internal radionuclide therapy

G Glatting, F. Mottaghy, G. Glatting, 2006, Nuklearmedizin.

Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies

G. Glatting, A. Buck, S. Reske, 2006, Nuklearmedizin.

188Re or 90Y‐labelled anti‐CD66 antibody as part of a dose‐reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study

H. Döhner, G. Glatting, A. Buck, 2005, British journal of haematology.

CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients

R. Schlenk, H. Döhner, S. Reske, 2004, British journal of haematology.

C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism.

S. Reske, M. Luster, R. Blagieva, 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Kinetics of Radioiodinated Isopropylamphetamine in Blood and Brain

S. Reske, H. Biersack, W. Eichelkraut, 1985 .

A 25-year-old woman with a gastric GIST and a PET-positive epicardial tumor

F. Mottaghy, S. Reske, M. Jeltsch, 2007, Nature Clinical Practice Oncology.

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.

F. Montorsi, M. Picchio, S. Reske, 2011, European urology.

Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.

Gerhard Glatting, Sven N Reske, G. Glatting, 2007, Radiology.

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters

Torsten Mattfeldt, Jörg Kotzerke, Gerhard Glatting, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Novel imaging techniques in NHL: Clinical results with PET imaging

S. Reske, I. Buchmann, 2001, Annals of Hematology.

Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors

A. Buck, S. Reske, S. Pauls, 2010, Archives of Orthopaedic and Trauma Surgery.

Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.

S. Reske, A. Guhlmann, M. Sarkar, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

FDG-PET and PET/CT in malignant lymphoma.

S. Reske, S N Reske, 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma

J Kotzerke, G Glatting, H. Schirrmeister, 2001, Cancer.

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.

J Kotzerke, S. Reske, M. Bangerter, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Extranodal malignant lymphoma: detection with FDG PET versus CT.

E. Merkle, S. Reske, A. Guhlmann, 1998, Radiology.

Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.

R. Schlenk, H. Döhner, G. Glatting, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma

F. Mottaghy, G. Glatting, A. Buck, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

J. Vose, B. Cheson, F. Mottaghy, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activation of intrinsic apoptotic pathway by Re-188 irradiation and paclitaxel in coronary artery smooth muscle cells.

G. Glatting, S. Reske, C. Friesen, 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

Claude Nahmias, Olivier Rascol, David J Brooks, 2003, Annals of neurology.

[For the benefit of the patient: the sentinel node excision].

S. Reske, R. Gutzmer, C. Löser, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma

F. Mottaghy, G. Glatting, A. Buck, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Usefulness of FDG-PET in diagnosing primary lymphoma of the liver.

H. Heimpel, E. Merkle, S. Reske, 1997, International journal of hematology.

Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma

F. Mottaghy, G. Glatting, A. Buck, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model

Gerhard Glatting, Sven N Reske, Peter Kletting, 2009, Journal of Nuclear Medicine.

Internal radionuclide therapy: The ULMDOS software for treatment planning.

Michael Landmann, Thomas Kull, Gerhard Glatting, 2005, Medical physics.

Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.

J Kotzerke, S. Reske, M. Bangerter, 1999, Acta oncologica.

Disturbed neural circuits in a subtype of chronic catatonic schizophrenia demonstrated by F-18-FDG-PET and F-18-DOPA-PET

H. Schirrmeister, S. Reske, A. Gerhard, 2001, Journal of Neural Transmission.

PTEN mutation: many birds with one stone in tumorigenesis.

S. Reske, Changxian Shen, Yonggang Zhou, 2008, Anticancer research.

Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma

F. Mottaghy, A. Buck, S. Reske, 2007, Nuklearmedizin.

Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

J Kotzerke, E. Merkle, S. Reske, 1997, Radiology.

FDG PET for imaging pericardial manifestations of Hodgkin lymphoma.

S. Reske, A. Wahl, H. Wandt, 2003, Clinical nuclear medicine.

Endovascular irradiation with the liquid beta-emitter Rhenium-188 to reduce restenosis after experimental wall injury.

S. Reske, V. Hombach, J. Wöhrle, 2001, Cardiovascular research.

Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.

Torsten Mattfeldt, Jörg Kotzerke, Gerhard Glatting, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?

H. Schirrmeister, G. Glatting, A. Buck, 2004, The Journal of thoracic and cardiovascular surgery.

Diagnosis — Methods for Evaluating Myocardial Microcirculation in Patients

A. Schmid, M. Phelps, S. Reske, 1982 .

Values and Limitations of 18F-Fluorodeoxyglucose–Positron-Emission Tomography with Preoperative Evaluation of Patients with Pancreatic Masses

G. Glatting, S. Reske, H. Brambs, 2000, Pancreas.

Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine

M. Schwaiger, G. Glatting, A. Buck, 2008, Clinical Cancer Research.

Biological characterisation of breast cancer by means of PET

Sven N. Reske, Torsten Mattfeldt, Andreas K. Buck, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Early D etection a nd A ccurate D escription o f E xtent o f Metastatic B one D isease i n B reast C ancer W ith F luoride Ion a nd P ositron E mission T omography

H. Schirrmeister, G. Glatting, S. Reske, 1999 .

Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions -Results from a Large Prospective Clinical Trial

F. Mottaghy, G. Glatting, A. Buck, 2008, Molecular Imaging and Biology.

Prerequisites for the Use of Antisense Oligonucleotides in Nuclear Medicine

S. Reske, M. Hildebrandt, 1996 .

Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease.

F. Mottaghy, S. Reske, C. Solbach, 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk?

H J Brambs, A Rieber, H. Schirrmeister, 2002, The British journal of radiology.

Imaging prostate cancer with 11C-choline PET/CT.

Sven Perner, Gerhard Glatting, Sven N Reske, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer

Sven N. Reske, Richard E. Hautmann, Jörg Kotzerke, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

F. Mottaghy, G. Glatting, A. Buck, 2010, Thyroid : official journal of the American Thyroid Association.

Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT

Christian Schumann, T. Wibmer, C. Schumann, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

PET Imaging of Breast Cancer Molecular Biomarkers

A. Buck, S. Reske, G. Lucignani, 2008 .

FDG-PET: procedure guidelines for tumour imaging

L. Mortelmans, S. Reske, R. Moncayo, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Molecular imaging of proliferation in malignant lymphoma.

T. Mattfeldt, F. Mottaghy, H. Döhner, 2006, Cancer research.

Experience with carbon-11 choline positron emission tomography in prostate carcinoma

Sven N. Reske, Jörg Kotzerke, Bernd Neumaier, 2000, European Journal of Nuclear Medicine.

Clinical relevance of imaging proliferative activity in lung nodules

T. Mattfeldt, F. Mottaghy, H. Schirrmeister, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer?

S. Reske, A. Guhlmann, G. Halter, 2000, The thoracic and cardiovascular surgeon.

Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).

S. Reske, A. Guhlmann, L. Sunder-Plassmann, 1997, Thorax.

Synthesis, characterization, and biodistribution of multiple 89Zr-labeled pore-expanded mesoporous silica nanoparticles for PET.

Larissa Miller, Barbara Witulla, S. Reske, 2014, Nanoscale.

Evaluation of [11C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer

F. Mottaghy, S. Reske, R. Kuefer, 2007, BJU international.

Lymph node staging for urinary bladder carcinoma with positron emission tomography (PET)

S. Reske, R. Hautmann, J. Kotzerke, 2016, Der Urologe.

Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.

S. Reske, A. Guhlmann, M. Sarkar, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

In vivo imaging of activated microglia using [11 C]PK11195 and positron emission tomography in patients after ischemic stroke

R Tomczak, G Glatting, G. Glatting, 2000, Neuroreport.

Detection of liver metastases from pancreatic cancer using FDG PET.

S. Reske, H. Beger, S N Reske, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Clinical Investigation : Genitourinary Cancer Value of PET / CT and MR Lymphography in Treatment of Prostate Cancer Patients With Lymph Node Metastases

S. Reske, B. Krause, Satoru Takahashi, 2022 .

Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: A 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study

Jan Kassubek, Arthur Wunderlich, Andrea G. Ludolph, 2008, NeuroImage.

Positron Emission Tomography with 18-F-Fluorodeoxyglucose in the Staging and Follow-Up of Lymphoma: Status quo and quo vadis

S. Reske, M. Bangerter, M. Griesshammer, 1999, Oncology Research and Treatment.

11C‐Choline positron‐emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer

F. Mottaghy, S. Reske, R. Hautmann, 2007, BJU International.

Impact of FDG-PET Computed Tomography for Surgery of Recurrent or Persistent Differentiated Thyroid Carcinoma

S. Reske, M. Luster, D. Henne-Bruns, 2012, Hormone and Metabolic Research.

– Prostate Cancer New Clinical Indications for 18 F / 11 C-choline , New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging : A Systematic Review of the Literature

M. Picchio, S. Reske, C. Stief, 2016 .

Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions - Results from a Large Prospective Clinical Trial

F. Mottaghy, G. Glatting, A. Buck, 2008, Molecular Imaging and Biology.

[11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

F. Mottaghy, A. Buck, S. Reske, 2009, World Journal of Urology.

Patients with in-stent restenoses

H. Kestler, F. Mottaghy, S. Reske, 2007, Nuklearmedizin.

A survey of PET activity in Germany during 1999

Gunnar Brix, Gerhard Glatting, G. Glatting, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[18F]FDG-PET in Patients with Alzheimer’s Disease: Marker of Disease Spread

H. Schirrmeister, S. Reske, G. Grön, 2004, Dementia and Geriatric Cognitive Disorders.

Catabolism of 15-(p-lodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) by isolated rat hearts

S. Reske, F. Knapp, R. Dudczak, 2004, European Journal of Nuclear Medicine.

Evaluation of mRNA Targeting by Labeled Oligonucleotides for Tumor-Diagnosis

H. Schirrmeister, S. Reske, J. Muth, 1999 .

[Reduction of regurgitation in aortic and mitral insufficiency by captopril in acute and long-term trials].

S. Reske, G. Fricke, H. Mattern, 1985, Schweizerische medizinische Wochenschrift.

Functional imaging of neuroendocrine tumours with PET

F. Mottaghy, S. Reske, 2006, Pituitary.

[Positron-emission tomography of the skeletal system using 18FNa: the incidence, pattern of the findings and distribution of benign changes].

H. Schirrmeister, K. Nuessle, S. Reske, 1998, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Reproducibility of a single-sample method for 99Tcm-MAG3 clearance under clinical conditions.

S. Reske, J. Kotzerke, K. Kleinschmidt, 1997, Nuclear medicine communications.

Intracoronary β-brachytherapy using a rhenium-188 filled balloon catheter in restenotic lesions of native coronary arteries and venous bypass grafts

F. Mottaghy, S. Reske, B. Krause, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Reticuloendothelial system Fc-receptor function in patients with immune thrombocytopenia after treatment with high dose intravenous immunoglobulin.

S. Reske, U. Budde, R. Schmidt, 2009, Scandinavian journal of haematology.

SPECT of the Brain Using Radiolabeled Amphetamines and a Rotating Gamma Camera

S. Reske, H. Biersack, W. Fröscher, 1985 .

Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep

S. Reske, C. Solbach, H. Machulla, 2014, Pharmaceuticals.

[Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F 18 fluorodeoxyglucose].

K. Nuessle, S. Reske, A. Rieber, 1999, Nuklearmedizin. Nuclear medicine.

FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies.

G. Glatting, S. Reske, H. Beger, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Positron emission tomography for detection and staging of malignant lymphoma.

H. Schirrmeister, S. Reske, F. Moog, 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy.

F. Mottaghy, G. Glatting, S. Reske, 2012, Medical physics.

Captopril-induced reduction of regurgitation fraction in aortic insufficiency: Acute and long-term effects

S. Reske, H. Biersack, H. Mattern, 1985 .

Determination of the immunoreactivity of radiolabeled monoclonal antibodies: a theoretical analysis.

G. Glatting, S. Reske, 2006, Cancer biotherapy & radiopharmaceuticals.

Indikationen der modernen PET/CT-Diagnostik

S. Reske, T. Kull, 2013, best practice onkologie.

Metabolism of 15 (p123I iodophenyl-)pentadecanoic acid in heart muscle and noncardiac tissues

S. Reske, J. Knust, H. Machulla, 2004, European Journal of Nuclear Medicine.

Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer

G. Glatting, S. Reske, B. Neumaier, 2003, Nuklearmedizin.